Biomaterials for promoting brain protection, repair and regeneration

被引:290
作者
Orive, Gorka [2 ,3 ,4 ]
Anitua, Eduardo [3 ]
Luis Pedraz, Jose [2 ,4 ]
Emerich, Dwaine F. [1 ]
机构
[1] InCytu Inc, Lincoln, RI 02865 USA
[2] Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, Vitoria 01006, Spain
[3] Inst Eduardo Anitua, BTI, Vitoria 01007, Spain
[4] SLFPB EHU, CIBER BBN, Networking Biomed Res Ctr Bioengn Biomat & Nanome, Vitoria 01006, Spain
关键词
CENTRAL-NERVOUS-SYSTEM; SOLID LIPID NANOPARTICLES; SPINAL-CORD-INJURY; NEUROPROTECTIVE GENE-THERAPY; CILIARY NEUROTROPHIC FACTOR; LATERAL-SCLEROSIS PATIENTS; DRUG-DELIVERY SYSTEMS; EMBRYONIC STEM-CELLS; HUNTINGTONS-DISEASE; MICROSPHERES PROMOTE;
D O I
10.1038/nrn2685
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Biomaterials are likely to have an increasingly important role in the treatment of nervous system disorders. Recently developed biomaterials can enable and augment the targeted delivery of drugs or therapeutic proteins to the brain, allow cell or tissue transplants to be effectively delivered to the brain and help to rebuild damaged circuits. Similarly, biomaterials are being used to promote regeneration and to repair damaged neuronal pathways in combination with stem cell therapies. Many of these approaches are gaining momentum because nanotechnology allows greater control over material-cell interactions that induce specific developmental processes and cellular responses including differentiation, migration and outgrowth.
引用
收藏
页码:682 / U47
页数:11
相关论文
共 98 条
  • [1] Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
    Aebischer, P
    Schluep, M
    Deglon, N
    Joseph, JM
    Hirt, L
    Heyd, B
    Goddard, M
    Hammang, JP
    Zurn, AD
    Kato, AC
    Regli, F
    Baetge, EE
    [J]. NATURE MEDICINE, 1996, 2 (06) : 696 - 699
  • [2] LONG-CIRCULATING (STERICALLY STABILIZED) LIPOSOMES FOR TARGETED DRUG-DELIVERY
    ALLEN, TM
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) : 215 - 220
  • [3] AOTA S, 1994, J BIOL CHEM, V269, P24756
  • [4] Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF
    Bachoud-Lévi, AC
    Déglon, N
    Nguyen, JP
    Bloch, J
    Bourdet, C
    Winkel, L
    Rémy, P
    Goddard, M
    Lefaucheur, JP
    Brugières, P
    Baudic, S
    Cesaro, P
    Peschanski, M
    Aebischer, P
    [J]. HUMAN GENE THERAPY, 2000, 11 (12) : 1723 - 1729
  • [5] Active targeting of brain tumors using nanocarriers
    Beduneau, Arnaud
    Saulnier, Patrick
    Benoit, Jean-Pierre
    [J]. BIOMATERIALS, 2007, 28 (33) : 4947 - 4967
  • [6] Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
    Begley, DJ
    [J]. PHARMACOLOGY & THERAPEUTICS, 2004, 104 (01) : 29 - 45
  • [7] The behavior of neural stem cells on biodegradable synthetic polymers
    Bhang, Suk Ho
    Lim, Jung Su
    Choi, Cha Yong
    Kwon, Yunhee Kim
    Kim, Byung-Soo
    [J]. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2007, 18 (02) : 223 - 239
  • [8] The support of neural stem cells transplanted into stroke-induced brain cavities by PLGA particles
    Bible, Ellen
    Chau, David Y. S.
    Alexander, Morgan R.
    Price, Jack
    Shakesheff, Kevin M.
    Modo, Michel
    [J]. BIOMATERIALS, 2009, 30 (16) : 2985 - 2994
  • [9] Solid lipid nanoparticles for targeted brain drug delivery
    Blasi, Paolo
    Glovagnoli, Stefano
    Schoubben, Aurelie
    Ricci, Maurizio
    Rossi, Carlo
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (06) : 454 - 477
  • [10] Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor:: Results of a phase I study
    Bloch, J
    Bachoud-Lévi, AC
    Déglon, N
    Lefaucheur, JP
    Winkel, L
    Palfi, S
    Nguyen, JP
    Bourdet, C
    Gaura, V
    Remy, P
    Brugières, P
    Boisse, MF
    Baudic, S
    Cesaro, P
    Hantraye, P
    Aebischer, P
    Peschanski, M
    [J]. HUMAN GENE THERAPY, 2004, 15 (10) : 968 - 975